First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study (CAPCET-III)

NCT06616259 PHASE3 NOT_YET_RECRUITING

This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided mCRC.

Details

Lead sponsor	Meng Qiu
Phase	PHASE3
Status	NOT_YET_RECRUITING
Enrolment	452
Start date	Thu Sep 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Cancer (CRC)
• Capecitabine
• Cetuximab

Interventions

• mCapOX plus Cetuximab
• mFOLFOX6 plus Cetuximab

Countries

China